Key statistics dashboard for Can-Fite BioPharma Ltd. (CANF). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19.
Stock Data
| Price | $2.24 |
| Market Cap | $3M |
| Beta | -0.10 |
| Exchange | AMEX |
| Country | IL |
Valuation Multiples
| P/E Ratio | -0.33 |
| Price / Book | 0.88 |
| P/S | 12.20 |
| P/FCF | -0.52 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -2402.96% |
| EBITDA Margin | -2402.47% |
| Operating Margin | -2402.96% |
| Net Margin | -2358.77% |
Financial Health
| Current Ratio | 3.60 |
| Quick Ratio | 3.60 |
| Cash Ratio | 1.34 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.61% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.22 |
| Book Value per share | 2.62 |
| Cash per share | 3.80 |
| FCF per share | -5.13 |
| Tangible Book Value per share | 2.62 |
| Dividend per share | 0.00 |
Related companies: BDRX · CLDI · CMND · CNSP · GRI · JAGX · KZIA
Explore sector: Healthcare · Biotechnology
More sections of CANF: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks